[News Article]Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial...
[News Article]Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial...
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
HQ +82-42-863-2017
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVE
Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.
https://am.asco.org/